CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

@article{Pfreundschuh2006CHOPlikeCP,
  title={CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.},
  author={Michael Pfreundschuh and Lorenz H. Tr{\"u}mper and Anders Osterborg and Ruth Pettengell and Marek Trněn{\'y} and Kevin Robert Imrie and David Ma and Devinder S Gill and Jan Walewski and P. Zinzani and Rolf Arno Stahel and Stein O Kvaloy and Ofer Shpilberg and Ulrich Jaeger and Mads Hansen and Tuula Lehtinen and Armando L{\'o}pez-Guillermo and Claudia Corrado and Adriana Scheliga and Noel Jean Milpied and Myriam Mendila and Michelle Rashford and Evelyn Kuhnt and Markus L{\"o}ffler},
  journal={The Lancet. Oncology},
  year={2006},
  volume={7 5},
  pages={379-91}
}
BACKGROUND The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined. We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients. METHODS 824 patients who were from 18 countries; aged 18-60 years; and who had no risk factors or one risk factor according to age-adjusted… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

10 Figures & Tables

Connections & Topics

Mentioned Connections BETA
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
CyclophosphamideIs component of chemotherapy regimenCHOP regimen
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
DoxorubicinIs component of chemotherapy regimenCHOP regimen
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
VincristineIs component of chemotherapy regimenCHOP regimen
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
B-Cell LymphomasMay be treated byrituximab
The role of rituximab in combination with different CHOP ( cyclophosphamide , doxorubicin , vincristine , and prednisone)-like chemotherapy regimens in young patients with good - prognosis diffuse large - B - cell lymphoma remains to be defined .
CHOP - like chemotherapy plus rituximab versus CHOP - like chemotherapy alone in young patients with good - prognosis diffuse large - B - cell lymphoma : a randomised controlled trial by the MabThera International Trial ( MInT ) Group .
Rituximab added to six cycles of CHOP is an effective treatment for young patients with good - prognosis diffuse large - B - cell lymphoma .
The primary endpoint was event - free survival ; secondary endpoints were response , progression under therapy , progression - free survival , overall survival , and frequency of toxic effects .
The primary endpoint was event - free survival ; secondary endpoints were response , progression under therapy , progression - free survival , overall survival , and frequency of toxic effects .
All Topics